CASI Pharmaceuticals director lists option holdings

CASI Pharmaceuticals, Inc. director Thomas Folinsbee filed a Form 3 detailing his initial beneficial ownership in stock options on the company’s ordinary shares.

Rhea-AI Filing Summary

CASI Pharmaceuticals, Inc. director Thomas Folinsbee filed a Form 3 detailing his initial beneficial ownership in stock options on the company’s ordinary shares. The options are fully vested and exercisable as of the filing date.

Disclosed positions include options over 11,231 ordinary shares at an exercise price of $1.26 per share expiring on July 21, 2035, and options over 20,000 shares at $3.59 per share expiring on June 26, 2034. Additional fully vested options cover 11,231 shares at $2.67 per share expiring on June 18, 2034, and 11,231 shares at $1.93 per share expiring on April 14, 2033.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Folinsbee Thomas

Role Director

Type	Security	Shares	Price	Value
holding	Option (right to buy)	--	--	--
holding	Option (right to buy)	--	--	--
holding	Option (right to buy)	--	--	--
holding	Option (right to buy)	--	--	--

Holdings After Transaction: Option (right to buy) — 53,693 contracts (Direct)

Footnotes (1)

1. F1. The options are fully vested and exercisable as of the date of this form.

Key Figures

Option holding at $1.26: 11,231 shares at $1.26 Largest option grant: 20,000 shares at $3.59 Option holding at $2.67: 11,231 shares at $2.67 +1 more

4 metrics

Option holding at $1.26 11,231 shares at $1.26 Fully vested options expiring July 21, 2035

Largest option grant 20,000 shares at $3.59 Fully vested options expiring June 26, 2034

Option holding at $2.67 11,231 shares at $2.67 Fully vested options expiring June 18, 2034

Option holding at $1.93 11,231 shares at $1.93 Fully vested options expiring April 14, 2033

Key Terms

Form 3, Option (right to buy, Ordinary Share, fully vested and exercisable

4 terms

Form 3 regulatory

"filed a Form 3 detailing his initial beneficial ownership"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Option (right to buy financial

"security title is listed as Option (right to buy) on ordinary shares"

Ordinary Share financial

"underlying security title for these options is Ordinary Share"

An ordinary share is a unit of ownership in a company that gives the holder a stake in its profits and usually the right to vote on key decisions. Think of it like a slice of a pizza where each slice entitles you to a portion of what’s left after bills are paid; value can rise or fall with the business and may pay dividends, so it matters to investors for income, growth and control.

fully vested and exercisable financial

"The options are fully vested and exercisable as of the date of this form"

FAQ

What does CASI (CASI) director Thomas Folinsbee report in his Form 3?

Thomas Folinsbee reports initial beneficial ownership of several stock option grants on CASI ordinary shares. All reported options are fully vested and exercisable, with exercise prices between $1.26 and $3.59 per share and expirations from 2033 through 2035.

How many CASI ordinary shares underlie Thomas Folinsbee’s lowest-price options?

Folinsbee holds options over 11,231 CASI ordinary shares at an exercise price of $1.26 per share. These fully vested options expire on July 21, 2035, providing long-dated potential exposure to CASI’s equity at that specified strike price.

What is the largest CASI option position reported by Thomas Folinsbee?

The largest single option position reported covers 20,000 CASI ordinary shares at an exercise price of $3.59 per share. This grant is fully vested and exercisable and is scheduled to expire on June 26, 2034, according to the Form 3 disclosure.

Are Thomas Folinsbee’s CASI stock options already vested?

Yes. A footnote states that all reported options are fully vested and exercisable as of the Form 3 date. This means Folinsbee can exercise each option grant at its stated exercise price any time before the respective expiration date.

What expiration dates apply to the CASI options held by Thomas Folinsbee?

The disclosed CASI options expire on April 14, 2033, June 18, 2034, June 26, 2034, and July 21, 2035. Each grant is fully vested and exercisable, giving multi‑year windows during which the director may choose to exercise the options.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/23/2026 - 06:00 AM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Folinsbee Thomas

(Last) (First) (Middle)

601 GATEWAY BLVD, SUITE 1250

(Street)

SSF CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
CASI Pharmaceuticals, Inc. [ CASIF ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)	(1)	04/14/2033	Ordinary Share	11,231	$1.93	D
Option (right to buy)	(1)	06/18/2034	Ordinary Share	11,231	$2.67	D
Option (right to buy)	(1)	06/26/2034	Ordinary Share	20,000	$3.59	D
Option (right to buy)	(1)	07/21/2035	Ordinary Share	11,231	$1.26	D

Explanation of Responses:

1. The options are fully vested and exercisable as of the date of this form.

	/s/ Thomas Folinsbee	04/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)